Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Depression may impact psoriatic arthritis (PsA) treatment response and lead to higher rates of biologic disease-modifying antirheumatic drug (bDMARD) Depression may impact PsA treatment response and lead to higher rates of bDMARD discontinuation, which may affect disease management and progression.